These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26212869)

  • 21. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
    McDermott J; Jimeno A
    Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas.
    Aalipour A; Advani RH
    Br J Haematol; 2013 Nov; 163(4):436-43. PubMed ID: 24111579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targets for Ibrutinib Beyond B Cell Malignancies.
    Berglöf A; Hamasy A; Meinke S; Palma M; Krstic A; Månsson R; Kimby E; Österborg A; Smith CI
    Scand J Immunol; 2015 Sep; 82(3):208-17. PubMed ID: 26111359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New approved indication for ibrutinib.
    Aschenbrenner DS
    Am J Nurs; 2014 Jun; 114(6):21. PubMed ID: 24869579
    [No Abstract]   [Full Text] [Related]  

  • 25. Ibrutinib: a paradigm shift in management of CLL.
    Badar T; Burger JA; Wierda WG; O'Brien S
    Expert Rev Hematol; 2014 Dec; 7(6):705-17. PubMed ID: 25387837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
    Roskoski R
    Pharmacol Res; 2016 Nov; 113(Pt A):395-408. PubMed ID: 27641927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ibrutinib for mantle cell lymphoma.
    Tucker DL; Rule SA
    Future Oncol; 2016 Feb; 12(4):477-91. PubMed ID: 26759179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
    Jain P; Kanagal-Shamanna R; San Lucas FA; Nastoupil L; Romaguera J; Fayad L; Oki Y; Westin JR; Medeiros LJ; Wang M; Fowler N
    Br J Haematol; 2018 Sep; 182(5):718-723. PubMed ID: 28771675
    [No Abstract]   [Full Text] [Related]  

  • 30. Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.
    Frustaci AM; Tedeschi A; Deodato M; Mazzucchelli M; Cairoli R; Montillo M
    Future Oncol; 2018 Apr; 14(8):681-697. PubMed ID: 29243946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
    Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
    Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Staphylococcus aureus meningitis in a patient with mantle cell lymphoma under treatment with ibrutinib.
    Diamantopoulos PT; Psichogiou M; Pantazatou A; Zervakis K; Rougala N; Giannakopoulou N; Daikos G; Viniou NA
    Ann Hematol; 2017 Jun; 96(6):1049-1050. PubMed ID: 28247056
    [No Abstract]   [Full Text] [Related]  

  • 33. Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.
    Lenz G
    J Clin Oncol; 2017 May; 35(13):1451-1452. PubMed ID: 28291389
    [No Abstract]   [Full Text] [Related]  

  • 34. Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia.
    Chan TS; Au-Yeung R; Chim CS; Wong SC; Kwong YL
    Ann Hematol; 2017 May; 96(5):871-872. PubMed ID: 28184982
    [No Abstract]   [Full Text] [Related]  

  • 35. Resistance mechanism for ibrutinib in marginal zone lymphoma.
    Epperla N; Shana'ah AY; Jones D; Christian BA; Ayyappan S; Maddocks K; Woyach JA
    Blood Adv; 2019 Feb; 3(4):500-502. PubMed ID: 30760464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-generation inhibitors of Bruton tyrosine kinase.
    Wu J; Liu C; Tsui ST; Liu D
    J Hematol Oncol; 2016 Sep; 9(1):80. PubMed ID: 27590878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
    Jones D; Woyach JA; Zhao W; Caruthers S; Tu H; Coleman J; Byrd JC; Johnson AJ; Lozanski G
    Leukemia; 2017 Jul; 31(7):1645-1647. PubMed ID: 28366935
    [No Abstract]   [Full Text] [Related]  

  • 38. Ibrutinib in B lymphoid malignancies.
    Smith MR
    Expert Opin Pharmacother; 2015; 16(12):1879-87. PubMed ID: 26165513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ibrutinib for the treatment of Waldenström macroglobulinemia.
    Chakraborty R; Kapoor P; Ansell SM; Gertz MA
    Expert Rev Hematol; 2015 Oct; 8(5):569-79. PubMed ID: 26138997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
    Gaudio E; Tarantelli C; Ponzoni M; Odore E; Rezai K; Bernasconi E; Cascione L; Rinaldi A; Stathis A; Riveiro E; Cvitkovic E; Zucca E; Bertoni F
    Oncotarget; 2016 Sep; 7(36):58142-58147. PubMed ID: 27494885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.